Kataoka A, Yokota D, Sugiyama T, Oda T, Nishida T, Yakushiji M
Department of Obstetrics and Gynecology, Kurume University School of Medicine.
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Oct;41(10):1523-9.
The antitumor activities of five anticancer drugs, at IC50 dosages cisplatin (CDDP), adriamycin (ADM), etoposide (VP-16), mitomycin C (MMC) and carboplatin (CBDCA) were studies an 7,12-dimethylbenz (a) anthracene induced rat ovarian cancer cell line (DMBA-OC-1) and a human ovarian serous adenocarcinoma cell line (KOC-1S). The IC50 dosage of anticancer drugs for DMBA-OC-1 was: CDDP 0.2 microgram/ml. ADM 0.04 microgram/ml, VP-16 3.0 microgram/ml, MMC 0.1 microgram/ml and CBDCA 10.0 micrograms/ml. The results of our study except those for MMC were parallel with those published on in vivo studies. The IC50 dosages of DMBA-OC-1 did not have enough antitumor activity for KOC-1S, whereas the original KOC-1S tumor strongly resisted the combination chemotherapy (CDDP, ADM and cyclophosphamide). Therefore, our findings suggested the possibility of the separation of multiple drug resistant clones from KOC-1S. These two cell lines had quite different antitumor activity characteristics.
研究了顺铂(CDDP)、阿霉素(ADM)、依托泊苷(VP - 16)、丝裂霉素C(MMC)和卡铂(CBDCA)这五种抗癌药物在7,12 - 二甲基苯并(a)蒽诱导的大鼠卵巢癌细胞系(DMBA - OC - 1)和人卵巢浆液性腺癌细胞系(KOC - 1S)中的抗肿瘤活性。抗癌药物对DMBA - OC - 1的IC50剂量分别为:顺铂0.2微克/毫升、阿霉素0.04微克/毫升、依托泊苷3.0微克/毫升、丝裂霉素C 0.1微克/毫升和卡铂10.0微克/毫升。我们的研究结果(除丝裂霉素C外)与已发表的体内研究结果一致。DMBA - OC - 1的IC50剂量对KOC - 1S没有足够的抗肿瘤活性,而原始的KOC - 1S肿瘤对联合化疗(顺铂、阿霉素和环磷酰胺)具有很强的抗性。因此,我们的研究结果提示了从KOC - 1S中分离多药耐药克隆的可能性。这两种细胞系具有相当不同的抗肿瘤活性特征。